Clinical trial
Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic…
NCT00326911 · Eli Lilly and Company, Industry · Terminated
Key facts
| NCT number | NCT00326911 |
|---|---|
| Title | Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer |
| Official title | A Phase II, Randomized, Open-Label Study of Cetuximab and Bevacizumab Alone or in Combination With Fixed-Dose Rate Gemcitabine as First-Line Therapy of Patients With Metastatic Adenocarcinoma of the Pancreas |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Pancreatic Cancer |
| Intervention type | Biological, Drug |
| Interventions | cetuximab, bevacizumab, gemcitabine |
| Enrollment | 61 |
| Start date | May 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | May 17, 2006 |
| Last update posted | May 25, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: